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TKA surgery (95% CI: 1.095-1.356). Patients concerned about experiencing pain (first 
several weeks following surgery) had significantly higher odds of delaying surgery 
(OR: 1.64, 95% CI: 0.881-3.06). 92% of survey respondents indicated they would seek 
surgeons who offered an effective non-opiate pain management option during the 
rehabilitation period. Gender, income level, and education level were not significant 
factors in the decision to delay TKA surgery. ConClusions: In a relatively wealthy, 
well-educated US-based population, the decision to delay a TKA is significantly 
influenced by patient concerns about interference with work and experiencing pain 
following TKA. Non-opioid pain management is important in selecting a surgeon.
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INCrEASED rATES Of SELf MONITOrING Of BLOOD GLUCOSE TrANSLATES TO 
BETTEr MArGINAL EffECTS ON HBA1C CONTrOL
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objeCtives: Despite numerous studies highlighting the importance of HbA1c con-
trol, literature quantifying the marginal effect of self-monitoring of blood glucose 
(SMBG) on HbA1c control is somewhat limited. Recognizing this knowledge gap, 
this study assessed the association between increased use of testing strips and 
glycemic control, taking into account insulin regimen, type I/II status, and other 
patient-level characteristics. Methods: Patient inclusion and exclusion criteria 
were adapted from HEDIS Comprehensive Diabetes Care guidelines. Commercially 
enrolled patients on insulin regimen (basal, bolus, or pre-mixed) with at least 
one diabetic strip fill between the ages of 18 to 75 years were identified from the 
HealthCore Integrated Research Database®. Continuous enrollment for 12 months 
pre/post the earliest testing strip fill (‘index’) was required. Clinical outcome was 
defined as most current HbA1c lab value within 1 year post-index period. Using 
average marginal effects (AME) analysis with bootstrapping, we estimated the like-
lihood of patient’s control (HbA1c < 8.0%) as number of testing strip fills increased, 
adjusting for age, gender, insulin regimen, and other variables. Results: Within 
this population, 45.8% of patients were unable to achieve control rates of < 8% dur-
ing the study period. However, patients with higher fill rates (> = 4 fills) were more 
likely to achieve control (60.9%) relative to a 44.0% control rate among those with 
low fill rates (< 4 fills). Using the AME analysis, each increase in fills was associ-
ated with a 2.5% increase in achieving control (AME: 2.5%, 95% C.I.: 2.1% - 2.8%, 
p< .001). The marginal effect between strip fills and HbA1c control was greater 
among type I patients (AME: 3.5%, 95% C.I.: 2.5% – 3.5%, p< .001). ConClusions: 
We found a statistically significant AME between testing strip fills and glucose 
control. These findings highlight the importance of efforts to encourage better 
SMBG among patients on insulin, with implications for improved patient outcomes 
and long term cost savings.
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USEr ExPErIENCE A NOVEL, BUT CrITICAL ELEMENT IN PAyEr AND 
PUrCHASEr VALUE ANALySIS Of MEDICAL TECHNOLOGIES
Garfield S., Zack L.
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objeCtives: Healthcare in the US is being reimagined to deliver technology enabled, 
high quality, cost-effective care. User experience (UX) drives clinician preferences 
and outcomes, while both clinical and economic impact drives payer/purchaser 
preferences. Elements of user experience include ease of use, reproducibility of 
results, and ability to easily and effectively understand directions and interfaces. 
All of which impact safety, reliability, and reproducibility- metrics important to 
payers. Methods: Data from 5 payer/purchaser studies of medical devices were 
reviewed to characterize the intersection of value drivers and impact variables. 
Expert evaluation techniques (Zhang 2003) were applied to identify key features that 
have an effect on both usability and predicted value. Results: Across studies, the 
usability of devices were tied to factors that impact clinical or cost-outcomes, but 
are not considered by payers and other purchasing groups routinely. Specifically, 
physician and patient preferences on usability criteria impacts error rates, proce-
dure time, patient satisfaction, and adherence. ConClusions: User experience 
criteria need to be embedded within value analyses by payers and purchasers to 
ensure technology innovations are optimized to deliver value along clinical and cost 
dimensions. This evaluation dimension helps further align coverage and purchasing 
decisions with quality incentives.
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TECHNOLOGIES
Waterman J., Taggart C., Garfield S.
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objeCtives: Digital health solutions are an emerging trend in healthcare delivery, 
with over $3 Billion dollars being invested in the space in the first three quarters of 
2014 alone, surpassing total medical device venture funding and representing 100% 
YoY growth. Healthcare, technology, and industry stakeholders are collaborating to 
develop tools that provide near patient monitoring, engagement, and interaction 
with providers with the expectation that these technologies will improve care and 
potentially decrease costs. However, little work has been done to develop methods 
to evaluate digital health solutions for payers and HTA decision-makers. The objec-
tive of this study was to determine the framework with which US payers will make 
coverage decisions for digital health technologies. Methods: In-depth interviews 
were conducted with 15 US payer and HTA decision-makers to determine prefer-
ences for evaluation frameworks for digital health technologies, drivers of value, 
evidence requirements, and economic impact expectations. Results: Most payers 
reported that they were currently experimenting with digital health technologies 
ity to use the inhaler in case of breathing difficulties, followed by features giving 
patients the reassurance about taken dose – precise dose counter and confirmation 
mechanism.
PMD58
COMPArISON Of THE IASP GrADING SySTEM AND S-LANSS IN 
IDENTIfICATION Of NEUrOPATHIC PAIN IN PATIENTS wITH CHrONIC LOw 
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objeCtives: Prevalence of neuropathic pain in patients with chronic low back pain is 
high. Screening for neuropathic pain is important because pharmacological manage-
ment differs from nociceptive pain. There are various methods to assess the neuro-
pathic pain. However these methods have shown different sensitivity and specificity 
in identifying the neuropathic pain. Present study compared the IASP grading system 
and S-LANSS in identification of neuropathic pain in patients with chronic low back 
pain. Methods: This is a prospective questionnaire based study where consecu-
tive chronic low back patients attending pain clinic of public tertiary care teaching 
hospital was included for the study. Each patient was examined by the physician 
and graded according to the IASP grading system about the certainty of neuropathic 
pain. Later patients ﬁlled the S-LANSS Questionnaire. Results: According to the 
IASP grading system, 45 patients (75%) classiﬁed as probable or deﬁnite neuropathic 
pain and 15 patients (25%) as unlikely neuropathic pain. According to the S-LANSS 
Questionnaire, 30 patients (50%) were classiﬁed as likely neuropathic pain and 30 
patients (50%) as unlikely neuropathic pain. All patients who were classiﬁed as neu-
ropathic pain according to S-LANSS questionnaire were also classiﬁed as deﬁnite or 
probable neuropathic pain by the IASP grading system. ConClusions: About 25% of 
neuropathic pain patients were not detected by S-LANSS. Self reported neuropathic 
pain assessment scale may miss patients with neuropathic pain.
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MEASUrING fUNCTION IN COGNITIVE IMPAIrMENT: A SUGGESTED 
TAxONOMy fOr CHArACTErIzING ASSESSMENT INSTrUMENTS
Ung B.L.1, Perfetto E.M.2, Tom S.1, Pickering M.K.2, Yang K.1, Higa S.1
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objeCtives: Various assessment instruments are used for gathering data on 
different functional domains (i.e., mental), from various reporters (e.g., patient 
or observer). The objective of this study was to create an inventory of functional 
instruments used in patients with cognitive impairment and to categorize them 
using a taxonomy that combines several approaches: functional domain, data 
reporter, and performance versus opinion based. Methods: A literature search 
was conducted using the following: English language, any date, “performance based 
measure”, “performance measures”, “performance tests”, “cognitive function tests”, 
“functional measures”, “functional tests”, “cognitive measures”, “functional assess-
ment”, “cognitive impairment”, “Alzheimer’s disease”. Three reviewers abstracted 
and evaluated retrieved studies to identify measure instruments and assign catego-
ries: 1. Addressing physical, mental, and/or social functioning; 2. Performance based 
(PerfO) or opinion based; and 3) Patient-reported (PRO), clinician-reported (ClinRO), 
or observer reported (ObsRO) outcome. Discrepancies among reviewers were decided 
through consensus. Results: The literature search led to the identification of 212 
measures used in cognitive impairment. Reviewers identified 134 as PerfOs. The 
remaining 78 opinion-based measures were categorized into PROs, ClinROs, and 
ObsROs. Overall, one, 17, and 152 measures assessed social, physical, and mental 
functioning, respectively. Forty-two measures assessed multiple domains. Within 
the 134 PerfOs, 13 were designed to assess physical, 109 mental, and one social 
functioning. Eleven included multiple functional domains. ConClusions: When 
measuring function in patients with cognitive impairment, it is important to rec-
ognize the wide range of instruments available and their characteristics. The tax-
onomy applied here, organizing functional-measure instruments used in cognitively 
impaired populations by various characteristics, is recommended as a starting point 
for characterizing tools. Researchers and clinicians can use such an approach to 
better understand the complexity of the measures as well as the strengths and 
limitations of these tools to guide them in selection and use, and interpretation 
of findings.
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PATIENT fACTOrS IN THE DECISION TO DELAy TOTAL kNEE ArTHrOPLASTy
Zhao R.1, Carlson A.M.2, Ilfeld B.M.3, Berend K.R.4, Stultz M.R.5
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objeCtives: Delaying a total knee arthroplasty (TKA) carries an increased likeli-
hood of poor rehabilitation outcomes. TKA candidates may choose to delay surgery 
for a variety of reasons including perceptions of pain and interference with activi-
ties due to pain. This study explores patients’ perspectives and factors related to 
the decision to delay a TKA procedure. Methods: Cross-sectional online survey 
conducted among U.S. patients with arthritis who were candidates for TKA. Survey 
questions related to pain severity and activity interference due to pain were taken 
from the Brief Pain Inventory (BPI); additional questions were related to pain man-
agement, the decision to delay TKA surgery and demographic information. Data was 
analyzed using descriptive statistics and logistic regression using SAS 9.3. Results: 
There were 654 respondents; mean age 64±7 years; 65.5% female; 62% with house-
hold income ≥ $50,000; 55.4% with bachelor or graduate degree. Logistic regression 
showed that interference with work and concerns for pain (pain in the first 3 days 
or pain in the first several weeks following surgery) were significant in predicting 
the decision to delay knee replacement surgery. A one unit increase in the interfer-
ence with work scale is associated with a 21.9% increase in the odds of delaying 
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drug therapy use in a practice setting in patients who did or didn’t receive the 
assay. Methods: Patients with initial visits for ER+, HER2- ESBC to the Regional 
Cancer Care Associates physician practice in 2009-2013 were identified using COTA, 
an oncology outcomes and cost tracking database. A case-control design was used to 
describe demographic, clinical, adjuvant CT, and supportive care therapy informa-
tion for patients < 70 years. Results: 158 Case patients who received the assay 
and 111 Controls who did not were identified. Cases were older, had larger tumors, 
and had more stage 1 tumors (p < 0.05). A significantly lower proportion in the 
Case group (21%) received CT compared to the Control group (56%; p< 0.001). The 
proportions of N- Case patients who received CT were 2%, 33%, and 100% in the 
Low, Intermediate and High Recurrence Score groups, respectively. Fifty of the 269 
patients (10 Cases, 40 Controls) were N+. In N+ Cases (n = 10), no Low risk group 
patients (n= 6) received CT, while all Intermediate and High risk group patients 
did. The proportion of Case patients who received pegfilgrastim or aprepitant was 
significantly lower than in the Control group (p< 0.001). The proportions of N+ Case 
patients receiving pegfilgrastim or aprepitant were also lower than in the N+ Control 
group. ConClusions: Physicians appear to be selective in using the 21-Gene assay 
in ESBC patients. Tested patients were less likely to receive CT and other supportive 
therapies. A majority of N+ patients tested had low Recurrence Score results and 
avoided CT, supporting potential utility of the assay in these patients.
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TrENDS IN ONCOLOGy BIOMArkEr TESTING IN EUrOPE (EU): OBSErVATIONS 
frOM BrEAST CANCEr (BC), METASTATIC NON-SMALL CELL LUNG CANCEr 
(MNSCLC) AND METASTATIC COLOrECTAL CANCEr (MCrC)
Narayanan S.1, Butcher A.2
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objeCtives: Assess the trends in Human Epidermal Growth Factor Receptor 2 
(HER2), Epidermal Growth Factor Receptor mutation (EGFRm) and KRAS biomarker 
testing in BC, mNSCLC and mCRC respectively in EU. Methods: A multi-country 
retrospective medical chart-review of BC/mNSCLC/mCRC patients were conducted 
by cancer treating physicians in Germany/France/Spain/Italy (4EU) and the UK; 
Data collection period was BC:2004-2013, mNSCLC/mCRC:2009-2014. Physicians 
were recruited from a geographically representative sample in each country. 
Approximately 10-25 eligible patients in respective tumor types on usual care 
anti-cancer regimen were identified by each physician within each of the four-
quarterly study observation-windows in respective years. Physicians abstracted 
data on patient demographics, disease status, treatment patterns and biomarker 
status .The analysis focused on HER2, EGFRm and KRAS testing trends. Results: 
An average of 7500 BC (4EU~6000; UK~1500), 3600 mNSCLC (4EU~3000; UK~600) and 
750 mCRC (4EU~600; UK~150) patient charts were abstracted per year. Percentage BC 
patients tested for HER2 increased in 4EU from 2004(70%) to 2009(89%) to 2013(97%), 
while the testing rates started relatively low in the UK initially (2004:23%; 2009:81%) 
and reached 4EU levels in 2013 (98%). EGFRm testing rates in mNSCLC increased 
in 4EU from December-2009(7%) to December-2011(53%) to December-2013(62%), 
and the UK testing rates increased during the corresponding period to be on-par 
despite starting slow (December-2009:2%; December-2011:33%; December-2013:62%). 
KRAS mutation testing rates in mCRC showed the largest difference between 
4EU (December-2009:61%; December-2011:89%; December-2013:92%) and UK 
(December-2009:6%; December-2011:26%; December-2013:62%) throughout the 
evaluation period. ConClusions: HER2/EGFRm/KRAS biomarker testing rates 
initially lagged behind in the UK in comparison to Germany/France/Italy/Spain, 
and the difference existed throughout the study evaluation period for KRAS, while 
HER2/EGFRm testing rates converged in 2013. Factors influencing these observed 
patterns (incl. access to medicines with relevant indications) needs further scru-
tiny to facilitate optimal care delivery utilizing targeted oncology therapeutics to 
benefit patients.
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THE rISE Of THE VALUE ANALySIS COMMITTEE AT US HOSPITALS, BETTEr Or 
wOrSE fOr MEDICAL DEVICE COMPANIES?
Hristova-Neeley D.1, Armstrong S.1, Garfield S.1, Ertel D.2
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objeCtives: In response to increased pressure to contain costs and optimize 
patient outcomes, hospitals have implemented standardized decision-making 
processes utilizing value analysis committees (VACs). In 2012, 64% of hospitals 
reported using some form of VAC. The objective of this analysis was to quantify 
the adoption of VAC, the product features considered impactful by VAC, timing 
of review and evidence requirements. Methods: Qualitative interviews (n= 40) 
and quantitative online survey (n= 76) were conducted with C-suite executives, 
purchasers, and clinician leads in the second half of 2014. Research participants 
were drawn from across the US, from a diverse selection of hospitals, including 
large/small, rural/urban and profit/non-profit. Outcomes of the research included 
adoption of VAC, triggers for VAC review, timing of review process, evidence 
requirements and implications for medical device companies. Results: 100% 
of hospitals surveyed report use of VAC for all new products being considered. 
Existing products may undergo a VAC when price or features change. Most prod-
ucts are brought to the VAC by the service line head, although one third of hospitals 
reported use of an automated system. Price of the product was identified as the 
most important consideration during VAC, though patient experience and other 
elements addressed by value-based purchasing were also mentioned. Clinical trial 
data was cited as most influential. However, most hospitals consider products in 
terms of their patient populations and specific context, making clinical trial data 
not optimally relevant to all hospitals. ConClusions: Because VACs are now a 
standard process at US hospitals, medical device companies must have a thorough 
understanding of the process and evidence requirements. Opportunities exist 
for increased communication between innovators and hospital decision-makers 
to align solutions with needs.Facility specific value propositions and data are 
frequently required to secure product approval.
in small populations but were not yet ready to make formal coverage decisions or 
support widespread adoption of specific technologies. Most payers were optimis-
tic about the promise of digital health solutions, with the greatest expectations 
for chronic disease management. Skepticism about incremental value and costs 
led most respondents to desire stringent evaluation criteria and evidence stand-
ards, with standard benchmarks of value preferred. Most expected digital health 
solutions would need to demonstrate decreased costs and improved clinical out-
comes. The most commonly desired attributes of digital health technologies are 
randomized clinical trial results, proven patient compliance, and EHR/EMR integra-
tion. ConClusions: Developing standardized evaluation criteria for digital health 
technologies will drive more consistent coverage outcomes and facilitate faster 
patient access to novel digital health technologies.
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objeCtives: Companion devices enable Mobile Health (mHealth) via remote moni-
toring of patients’ biometrics. By 2020, the global mHealth market is estimated to 
reach $6.28 billion. While mHealth is expected to revolutionize delivery of patient 
care, especially for chronic diseases such as diabetes or asthma, it has not realized 
its full potential. To that end, the objectives of this study were to: 1) Characterize 
benefits that companion devices may deliver to key stakeholders, including patients, 
Health Care Professionals (HCPs), payers, and drug manufacturers; 2) Determine how 
HCPs currently utilize companion devices and key unmet needs; 3) Identify perceived 
roadblocks by payers in coverage & reimbursement of companion devices. Methods: 
Health Technology Assessments (HTAs) and guidelines published between 2010 and 
2014, and publications archived in MEDLINE and PubMed were analyzed to assess 
potential benefits, challenges, and historical valuation of companion devices. 
Additionally, approved companion devices were evaluated to assess their coverage 
and reimbursement and associated evidence requirements in the US and 5 major 
EU markets. Results: Companion devices can potentially deliver benefits across 
the continuum of care that may be categorized into three areas: patient manage-
ment (adherence and compliance), disease management (clinic visits and trend 
alerts), drug management (dosage and clinical events). Current barriers to adoption 
appear to be primarily cost of technology, potentially increased liability exposure, 
compliance with patient confidentiality, challenge in demonstrating positive budget 
impact, and importantly, lack of optimal reimbursement (separate vs bundled pay-
ment). ConClusions: While relatively nascent, companion devices are expected to 
play a role along the full continuum of patient care: from prevention, diagnosis, treat-
ment, to monitoring. As such, this study indicated that the integration of companion 
devices with care plans is potentially hinged around three key issues: a) patient edu-
cation and awareness, b) physician engagement via streamlined clinical workflow, 
and c) demonstration of long-term economic benefits to payers.
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PrEGNANCy. EVIDENCE BASED META-ANALySIS
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objeCtives: Pregnancy poses a high risk of thyroid dysfunction (TD) causing 
adverse outcomes in mother, fetus and neonate. This makes screening pregnant 
women for TD essential. Universal screening (US) aims to screen all women in 
contrast to targeted screening (TS) where only women at high-risk get tested for TD 
during pregnancy. Existing guidelines do not recommend US. Thus we performed 
meta-analysis to clarify this moot question whether US should be recommended 
for screening TD in pregnancy. Methods: All original research articles compar-
ing the two approaches to detect TD in pregnancy were searched from databases 
PubMed, EBSCO and Cochrane library. Effect estimate is reported as loss ratio (LR) 
signifying missed cases. Missed cases are women considered as low risk during TS. 
Subgroup analysis was done for hyperthyroid and overall thyroid disorder. Further 
sensitivity and specificity analysis was also done. Data is analyzed using CMA 
2.0. Results: Total of 9 studies including 10,888 women was included in present 
analysis. As significant heterogeneity was found between studies (P ‹ 0.001, I2 = 
0.99), random-effects model was used. 46% hypothyroid cases were missed if TS 
was performed instead of US (RR 0.46 (95% CI (0.35 to 0.61), P ≤ 0.001). Sensitivity 
analyses showed (RR 0.40 (95% CI (0.27 to 0 0.55), P≤ 0.001) Specificity test has 
confirmed it (RR 0.31 (95% CI (0.20 to 0.47), P≤ 0.001). Similar trends were seen in 
hyperthyroid (RR 0.56 (95% CI (0.51 to 0.65), P≤ 0.001) and over-all TD (RR 0.49 (95% 
CI (0.43 to 0.60), P≤ 0.001). ConClusions: Almost half of the cases were missed 
on TS. The present pooled analysis recommends US to identify overall TD as well 
as hypothyroid cases in pregnancy. This serves as a strong evidence for inclusion 
of US into guidelines.
PMD66
CHArACTErIzATION Of EArLy STAGE BrEAST CANCEr PATIENT 
MANAGEMENT IN A PrACTICE SETTING wITH THE 21-GENE BrEAST CANCEr 
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objeCtives: Patients with low risk 21-Gene Breast Cancer Assay results can safely 
avoid chemotherapy (CT), as has been shown in protocol-driven studies. This study’s 
objective was to compare, using practice management data, CT and supportive 
